CUTIVATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cutivate, and when can generic versions of Cutivate launch?
Cutivate is a drug marketed by Fougera Pharms and is included in three NDAs.
The generic ingredient in CUTIVATE is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cutivate
A generic version of CUTIVATE was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.
Summary for CUTIVATE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 85 |
Clinical Trials: | 3 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CUTIVATE |
What excipients (inactive ingredients) are in CUTIVATE? | CUTIVATE excipients list |
DailyMed Link: | CUTIVATE at DailyMed |
Recent Clinical Trials for CUTIVATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fougera Pharmaceuticals Inc. | Phase 4 |
Children's Hospital of Philadelphia | Phase 4 |
Novartis Pharmaceuticals | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for CUTIVATE
Paragraph IV (Patent) Challenges for CUTIVATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CUTIVATE | Lotion | fluticasone propionate | 0.05% | 021152 | 1 | 2008-07-28 |
US Patents and Regulatory Information for CUTIVATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fougera Pharms | CUTIVATE | fluticasone propionate | CREAM;TOPICAL | 019958-001 | Dec 18, 1990 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fougera Pharms | CUTIVATE | fluticasone propionate | LOTION;TOPICAL | 021152-001 | Mar 31, 2005 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fougera Pharms | CUTIVATE | fluticasone propionate | OINTMENT;TOPICAL | 019957-001 | Dec 14, 1990 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CUTIVATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Fougera Pharms | CUTIVATE | fluticasone propionate | OINTMENT;TOPICAL | 019957-001 | Dec 14, 1990 | ⤷ Try a Trial | ⤷ Try a Trial |
Fougera Pharms | CUTIVATE | fluticasone propionate | CREAM;TOPICAL | 019958-001 | Dec 18, 1990 | ⤷ Try a Trial | ⤷ Try a Trial |
Fougera Pharms | CUTIVATE | fluticasone propionate | LOTION;TOPICAL | 021152-001 | Mar 31, 2005 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CUTIVATE
See the table below for patents covering CUTIVATE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2002528418 | ⤷ Try a Trial | |
Spain | 8402317 | ⤷ Try a Trial | |
South Korea | 850000969 | ⤷ Try a Trial | |
Austria | 395429 | ⤷ Try a Trial | |
Finland | 810444 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CUTIVATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1519731 | 92269 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
2506844 | 132018000000341 | Italy | ⤷ Try a Trial | PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117 |
2506844 | SPC/GB18/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117 |
1305329 | SPC/GB08/026 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116 |
2506844 | LUC00077 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |